RTY-694 shows promise in models of liver, bile duct diseases PFIC, PSC
In a mouse model of progressive familial intrahepatic cholestasis type 2 (PFIC2), Rectify Pharmaceuticals’ experimental oral therapy RTY-694 reduced markers of slowed bile flow…